Noom vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Noom is a digital weight health program combining psychology-based behavioral coaching, food logging, and human coaching to help members build sustainable healthy habits.
About
Noom is a digital health company founded in 2008 that has grown into one of the most widely used weight management platforms, serving millions of members through its psychology-driven approach to behavior change. The platform combines daily lessons on cognitive behavioral techniques, food logging with a traffic-light color-coding system, personal coaching from trained health coaches, and group support to help members change their relationship with food and exercise. Noom raised over $540M and reached a $3.7B valuation, establishing it as a leading consumer digital health company. The company has expanded beyond weight loss into a broader weight health platform addressing both weight management and weight-related conditions including type 2 diabetes management with its Noom Med offering that includes GLP-1 medication prescribing. As GLP-1 medications like Ozempic and Wegovy have transformed the weight loss market, Noom has positioned its behavioral coaching as essential to sustainable results alongside medication. The platform serves both direct-to-consumer subscribers and employer health plans that offer Noom as a weight management benefit for their workforces.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.